Senior insider sale
Chief Operating Officer at NEWAMSTERDAM PHARMA CO N.V. — senior position signals high conviction
$11.91M
615.15K shares
What this filing means
KLING DOUGLAS F plans to sell 615.15K shares of NEWAMSTERDAM PHARMA CO N.V. valued at approximately $11.91M. Form 144 is a notice of intent to sell restricted or control securities — not a mandatory transaction. This filing provides advance warning of potential selling pressure.
Filed: 5/15/2025ACC: 0001968582-25-000363
Officer· Chief Operating Officer
Since Dec 2023
615.15K
Shares to sell
$11.91M
Approx. market value
298.61K
Acquired (3 months)
1
Planned
5 completed
Securities Acquired — Last 3 Months1
Stock Option Exercise
Cash
5/15/2025
298.61KTotal acquired298.61K
| Acquisition Date | Type | Amount Acquired | Gift |
|---|---|---|---|
5/15/2025 | Stock Option Exercise Cash | 298.61K | — |
| Total | 298.61K | ||
Planned & Completed Dispositions6
Completed
—Completed
Units to sell
100K
Market value
$1.60M
4/15/2025
—Completed
Units to sell
16.54K
Market value
$378.7K
3/26/2025
—Completed
Units to sell
100K
Market value
$2.34M
3/17/2025
—Completed
Units to sell
9.22K
Market value
$182.9K
2/19/2025
—Completed
Units to sell
90.78K
Market value
$1.81M
2/18/2025
Planned — Approximate Date
NasdaqPlanned
Units to sell
298.61K
Market value
$5.60M
5/15/2025
Total
Units
615.15K
Value
$11.91M
| Date | Units to Sell | Approx. Market Value | Exchange | Status |
|---|---|---|---|---|
| Completed | ||||
4/15/2025 | 100K | $1.60M | — | Completed |
3/26/2025 | 16.54K | $378.7K | — | Completed |
3/17/2025 | 100K | $2.34M | — | Completed |
2/19/2025 | 9.22K | $182.9K | — | Completed |
2/18/2025 | 90.78K | $1.81M | — | Completed |
| Planned — Approximate Date | ||||
5/15/2025 | 298.61K | $5.60M | Nasdaq | Planned |
| Total | 615.15K | $11.91M | ||